title: Effects of amyloid precursor protein 17 peptide on the protection of diabetic encephalopathy and improvement of glycol metabolism in the diabetic rat.
abstract: Researchers have proposed that amyloid precursor protein 17 peptide (APP17 peptide), an active fragment of amyloid precursor protein (APP) in the nervous system, has therapeutic effects on neurodegeneration. Diabetic encephalopathy (DE) is a neurological disease caused by diabetes. Here we use multiple experimental approaches to investigate the effect of APP17 peptide on changes in learning behavior and glycol metabolism in rats. It was found that rats with DE treated by APP17 peptide showed reversed behavioral alternation. The [(18)F]-FDG-PET images and other results all showed that the APP17 peptide could promote glucose metabolism in the brain of the DE rat model. Meanwhile, the insulin signaling was markedly increased as shown by increased phosphorylation of Akt and enhanced GLUT4 activation. Compared with the DE group, the activities of SOD, GSH-Px, and CAT in the rat hippocampal gyrus were increased, while MDA decreased markedly in the DE + APP17 peptide group. No amyloid plaques in the cortex and the hippocampus were detected in either group, indicating that the experimental animals in the current study were not suffering from Alzheimer's disease. These results indicate that APP17 peptide could be used to treat DE effectively.
authors.affiliation: Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
authors.forename: Heng
authors.initials: H
authors.lastname: Meng
authors.forename: Duo
authors.initials: D
authors.lastname: Zhang
authors.forename: Haishan
authors.initials: H
authors.lastname: Yang
mesh_terms: D016564:Amyloid beta-Protein Precursor / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D006018:Glycols / Q000378:metabolism*; D007858:Learning / Q000187:drug effects; D008297:Male; D009410:Nerve Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D016564:Amyloid beta-Protein Precursor; D001786:Blood Glucose; D006018:Glycols; D010446:Peptide Fragments; C446879:amyloid beta-protein precursor 695 (319-339); D051057:Proto-Oncogene Proteins c-akt